Dow Down0.25% Nasdaq Down0.14%

Avanir Pharmaceuticals, Inc. (AVNR)

-NasdaqGS
11.95 Up 0.34(2.93%) Sep 29, 4:00PM EDT
|After Hours : 11.99 Up 0.04 (0.33%) Sep 29, 7:56PM EDT
ProfileGet Profile for:
Avanir Pharmaceuticals, Inc.
20 Enterprise
Suite 200
Aliso Viejo, CA 92656
United States - Map
Phone: 949-389-6700
Fax: 949-389-6701
Website: http://www.avanir.com

Details 
Index Membership:N/A
Sector:Healthcare
Industry:Drugs - Generic
Full Time Employees:267

Business Summary 

Avanir Pharmaceuticals, Inc., together with its subsidiaries, is engaged in acquiring, developing, and commercializing novel therapeutic products for the treatment of central nervous system disorders primarily in the United States. It primarily offers NUEDEXTA, a dual N-methyl-D-aspartate receptor antagonist and sigma-1 agonist for the treatment of pseudobulbar affect; and Docosanol 10% cream, an over-the-counter product for the treatment of cold sores. The company’s clinical development stage products comprise AVP-923, which has completed Phase II clinical trials for the treatment of central neuropathic pain in patients with multiple sclerosis; is in Phase II clinical trials for the treatment of agitation in patients with Alzheimer’s disease; and is in Phase II clinical trials for the treatment of levodopa-induced-dyskinesia in Parkinson’s disease, as well as completed Phase III trials for the treatment of patients with diabetic peripheral neuropathic pain. It is also developing AVP-786, a Phase I clinical trial novel investigational drug product for the treatment of neurologic and psychiatric disorders; and AVP-825, an investigational drug-device combination product, which is in Phase III clinical trials, to treat acute migraine. The company has a license agreement with Concert Pharmaceuticals, Inc. to develop and commercialize deuterium-modified dextromethorphan for the potential treatment of neurologic and psychiatric disorders, as well as rights to other deuterium-modified dextromethorphan compounds; and a license agreement with OptiNose AS for the development and commercialization of a novel breath powered intranasal delivery system to treat acute migraine. Avanir Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Aliso Viejo, California.

Key Statistics


Company Websites 
Home Page
Search Yahoo! for:
More on Avanir Pharmaceuticals, Inc.

Corporate Governance 
Avanir Pharmaceuticals, Inc.’s ISS Governance QuickScore as of Sep 1, 2014 is 6. The pillar scores are Audit: 1; Board: 3; Shareholder Rights: 7; Compensation: 8.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
 PayExercised
Mr. Keith A. Katkin , 43
Chief Exec. Officer, Pres, Director and Member of Exec. Committee
921.00K532.00K
Ms. Christine G. Ocampo CPA, 42
Principal Financial Officer, Principal Accounting Officer, VP of Fin. and Sec.
371.00K138.00K
Dr. Joao Siffert M.D., 51
Chief Medical Officer and Sr. VP of R&D
557.00K49.00K
Mr. Rohan Palekar , 48
Chief Commercial Officer and Sr. VP
609.00K0.00
Ms. Elona Kogan Esq., 45
VP of Legal Affairs
N/AN/A
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders